MedTrace Logo

Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

NCT00418730 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2008-05-20

No results posted yet for this study

Summary

The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.

Conditions

Interventions

DRUG

tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days

Sponsors & Collaborators

  • Neosil, Inc.

    lead INDUSTRY

Principal Investigators

  • Johannes Gassmueller, MD · Bioskin GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-10-31
Completion
2008-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00418730 on ClinicalTrials.gov